FDA to Host Meeting on Patient-Focused Drug Development for Opioid Use Disorder

The Food and Drug Administration (FDA) will host a public meeting April 17 on patient-focused drug development for opioid use disorder (OUD), in collaboration with the National Institute on Drug Abuse.

The FDA is also working closely with patient advocacy and community organizations to encourage participation from people with OUD. The FDA is interested in learning patients’ perspectives on OUD, including the effects on their health and well-being that have the greatest impact on daily life, their experience using prescription medical treatments and other treatments or therapies for OUD, and challenges or barriers to accessing or using medical treatments for the disorder.

The meeting will take place at FDA White Oak Campus, 10903 New Hampshire Ave., Building 31, Room 1503A (Great Room), Silver Spring, Maryland, from 10 a.m. to 4 p.m. Click here to register. Early registration is recommended. The webcast of the meeting will be available here.

Heroin & the Opioid Epidemic: From Understanding to Action

Heroin and other opioids are ravaging communities across America. Deaths from heroin increased 328% between 2010 and 2015, and drug deaths from fentanyl and other synthetic opioids are now seeing a rise as well.

Leave a Comment

Please leave a comment below to contribute to the discussion. If you have a specific question, please contact a Parent Specialist, who will provide you with one-on-one help.

Your email address will not be published. Required fields are marked *